Clinical trial
Insulin Glargine in Type 2 Diabetic Patients
NCT00347100 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00347100 |
|---|---|
| Title | Insulin Glargine in Type 2 Diabetic Patients |
| Official title | Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy |
| Acronym | TARGET |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin Glargine, Glyburide, Glyclazide, Glimiperide, Glipizide, Metformin |
| Enrollment | 387 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2008 |
| First posted | Jul 4, 2006 |
| Last update posted | Sep 15, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: